Inhaled carbon monoxide prevents graft-induced intimal hyperplasia in swine.
BACKGROUND
Arteriovenous grafts often fail due to stenosis caused by venous anastomotic intimal hyperplasia (IH) and vascular smooth muscle cell (VSMC) proliferation. We examined the effects of inhaled carbon monoxide (CO), a product of heme-oxygenase-1 degradation of heme, on IH in a porcine arteriovenous graft model.


METHODS
Eighteen Yorkshire pigs were divided into three groups (N = 6/group): (1) CO 100 ppm preoperatively for 1 h; (2) CO 250 ppm preoperatively for 1 h and intraoperatively; and (3) air-treated controls. Animals underwent end-to-side placement of polytetrafluoroethylene grafts connecting the common femoral artery and vein in both groins. Intimal thickness of the venous anastomosis at 30 days was measured blinded. The effect of CO on pig VSMC proliferation was studied in cell culture using [(3)H]thymidine incorporation.


RESULTS
Pigs in the group receiving CO 250 ppm showed significantly less IH compared to animals in the group receiving 100 ppm and the air-treated group (267.5 +/- 21.4, 824 +/- 145.8, and 914.8 +/- 133.7 pixels, respectively, P < 0.0001). This effect was not observed when comparing the 100 ppm group to the air-treated group. COHb levels were significantly elevated in the 100 ppm and 250 ppm compared to air-treated pigs (5.8 +/- 0.47, 13.2 +/- 1.0 versus 2.3 +/- 0.11%, respectively, P < 0.001). Oxygen saturation, respiratory rate, and hemodynamics were not significantly different between the groups. CO induced VSMC growth arrest compared to air in vitro (11.9 +/- 4 versus 20.3 +/- 5 10(3) counts/min/well, P < 0.01).


CONCLUSIONS
A single exposure to a low concentration of inhaled CO (250 ppm) confers protection against intimal proliferation of VSMCs when given perioperatively in a clinically relevant model of arteriovenous grafts. These data are the first to suggest, in a clinically relevant model, the potential role for CO in clinical applications.
Ramlawi
Basel
B
Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.
Scott
Jeffrey R
JR
Feng
Jun
J
Mieno
Shigetoshi
S
Raman
Kathleen G
KG
Gallo
David
D
Csizmadia
Eva
E
Yoke Chin
Beek
B
Bach
Fritz H
FH
Otterbein
Leo E
LE
Sellke
Frank W
FW
D000280:Administration, Inhalation; D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology*; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation; D002248:Carbon Monoxide / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D005263:Femoral Artery; D005268:Femoral Vein; D006083:Graft Occlusion, Vascular / Q000188:drug therapy* / Q000517:prevention & control*; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D011138:Polytetrafluoroethylene; D034421:Sus scrofa; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology
D000963:Antimetabolites; D002248:Carbon Monoxide; D011138:Polytetrafluoroethylene